Form D · Biotechnology
BG Medicine, Inc.
Waltham, MA · CIK 0001407038
Offering snapshot reported May 21, 2015 · SEC filing
- Reported sold
- $500K Offering amount: $2.5M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 12, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 21, 2015 | Initial | $500,000 | No comparison | 3 | SEC filing |
| Apr 14, 2010 | Initial | $2,000,000 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-240369
Source: Form D, filed May 21, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Aram Adourian | Executive |
| Noubar Afeyan | Director |
| Harrison Bains | Director |
| Stephane Bancel | Director |
| Stephen Hall | Executive |
| Timothy Harris | Director |
| Pieter Muntendam | Director, Executive |
| Stelios Papadopoulos | Director |
| Michael W. Rogers | Executive |
| Paul Sohmer | Director, Executive |
| Pieter Van Der Meer | Director |
| Harry Wilcox | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
880 Winter Street Suite 210
Waltham, MA, 02451
Waltham, MA, 02451